A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries

Description

The purpose of this study is to evaluate the effectiveness, safety, and tolerability of SUZ for acute pain after laparoscopic procedures of the intraperitoneal or retroperitoneal cavities or arthroscopic orthopedic procedures.

Conditions

Acute Pain

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to evaluate the effectiveness, safety, and tolerability of SUZ for acute pain after laparoscopic procedures of the intraperitoneal or retroperitoneal cavities or arthroscopic orthopedic procedures.

A Phase 4, Open-label, Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine As Part of Multimodal Therapy for Acute Pain After Laparoscopic Procedures of the Intraperitoneal or Retroperitoneal Cavities or Arthroscopic Orthopedic Procedures

A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries

Condition
Acute Pain
Intervention / Treatment

-

Contacts and Locations

Scottsdale

Scottsdale Clinical Trials, Scottsdale, Arizona, United States, 85260

Little Rock

Woodland International Research Group, Little Rock, Arkansas, United States, 72211

Durham

Eximia Research-Durham, Durham, North Carolina, United States, 27704

Wilmington

Seaside Clinical Research Institute, Wilmington, North Carolina, United States, 28412

Bellaire

HD Research LLC | First Surgical Hospital, Bellaire, Texas, United States, 77401

Houston

Memorial Hermann Village, Houston, Texas, United States, 77043

Norfolk

Tidewater Clinical Research, Norfolk, Virginia, United States, 23502

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m\^2)
  • * Scheduled to undergo a procedure that is in one of the following categories that would typically be treated with opioid therapy for at least 72 hours postoperatively such as
  • * Laparoscopic intraperitoneal or retroperitoneal procedure
  • * Arthroscopic orthopedic procedure

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Vertex Pharmaceuticals Incorporated,

Study Record Dates

2026-01-15